Uncategorized
Experimental drug for wet macular degeneration shows promise
LONDON (Reuters) - Fovista, an experimental drug from private U.S. biotech Ophthotech, showed
impressive results when added to Roche's Lucentis (ranibizumab) in a large mid-stage clinical trial.